Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study.
Aurora ZanghìEmanuele D'AmicoFrancesco PattiCarlo AvolioPublished in: International journal of environmental research and public health (2022)
In a real-world setting, in patients with non-active SPMS, the maintaining or switching to the licensed interferon beta 1b did not reduce the risk of reaching confirmed EDSS 7.0.
Keyphrases